Trius Appoints Seth Fischer to Its Board of Directors

Trius Appoints Seth Fischer to Its Board of Directors

Risa Stack Announces Planned Departure From the Trius Board

SAN DIEGO, April 3, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) announced today the appointment of Seth H. Z. Fischer to its
Board of Directors. Mr. Fischer was the former Company Group Chairman Johnson
& Johnson, Worldwide Franchise Chairman Cordis Corporation responsible for the
Cardiovascular Device Business until his retirement in 2012. The Company also
announced the departure of Risa Stack, Ph.D., General Manager with GE
Healthymagination, from its Board, which will be effective as of May 22, 2013
following the Company's 2013 Annual Meeting of Stockholders.Dr. Stack is
stepping down to focus her efforts on her role at GE.

"We are very pleased to welcome Seth Fischer to our Board of Directors, and
believe his deep commercial experience and industry knowledge will strengthen
the capabilities of our Board to advise on the planned commercialization of
tedizolid, pending regulatory approval," stated David S. Kabakoff, Ph.D.,
Chairman of the Board of Trius."We would also like to thank Risa Stack for
her outstanding service to Trius and we wish her continued success at GE."

Seth H. Z. Fischer has three decades of healthcare experience in the
pharmaceutical and medical device industry.Mr. Fischer served in positions of
increasing responsibility with Johnson & Johnson until his retirement in 2012.
Most recently Mr. Fischer served as Company Group Chairman Johnson & Johnson,
Worldwide Franchise Chairman Cordis Corporation from 2008 to 2012, which
included responsibility for Cordis and Biosense Webster. Previously, he served
as Company Group Chairman North America Pharmaceuticals from 2004 to 2007. In
this position he had responsibilities for Ortho-McNeil Pharmaceuticals,
Janssen and Scios. Prior to this position, Mr. Fischer served as President of
Ortho-McNeil Pharmaceuticals from 2000 to 2004. His operating responsibilities
encompassed the commercialization of products in multiple therapeutic
categories including the oral and IV anti-infectives Levaquin^® and Floxin^®,
cardiovasculars, CNS, analgesics and women's health.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas.For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the anticipated effects
of the addition of Mr. Fischer to the Company's Board of Directors and the
Company's commercialization efforts. Risks that contribute to the uncertain
nature of the forward-looking statements include: the accuracy of Trius'
estimates regarding expenses, future revenues and capital requirements; the
success and timing of Trius' preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries; changes in
Trius' plans to develop and commercialize its product candidates; additional
ongoing or planned clinical trials of tedizolid phosphate may produce negative
or inconclusive results; Trius may decide, or the FDA may require Trius, to
conduct additional clinical trials or to modify Trius' ongoing clinical
trials; Trius may experience delays in the commencement, enrollment,
completion or analysis of clinical testing for its product candidates, or
significant issues regarding the adequacy of its clinical trial designs or the
execution of its clinical trials, which could result in increased costs and
delays, or limit Trius' ability to obtain regulatory approval; the third
parties with whom Trius has partnered with for the development of tedizolid
phosphate and upon whom Trius relies to conduct its clinical trials and
manufacture its product candidates may not perform as expected; tedizolid
phosphate may not receive regulatory approval or be successfully
commercialized; unexpected adverse side effects or inadequate therapeutic
efficacy of tedizolid phosphate could delay or prevent regulatory approval or
commercialization; Trius' ability to obtain and maintain intellectual property
protection for its product candidates; and the loss of key scientific or
management personnel. These and other risks and uncertainties are described
more fully in Trius' most recent Form 10-K, Forms 10-Q and other documents
filed with the United States Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in such filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Trius undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507
 
Press spacebar to pause and continue. Press esc to stop.